Associazione Oasi Maria SS. Onlus

Their core work

Associazione Oasi Maria SS. Onlus is an Italian non-profit care and rehabilitation center based in Troina, Sicily, specializing in residential and clinical care for people with intellectual disabilities and neurodevelopmental conditions. In EU research, they function as a clinical site — providing access to patient populations with autism spectrum disorder and Down syndrome, which is rare and valuable for clinical trial recruitment. Their most substantial research engagement is the ICOD project, where they contribute to a first-in-human clinical study testing CB1 receptor inhibitors to improve cognition in Down syndrome. For consortium builders, they represent a direct bridge between research and the real-world patient communities these therapies are meant to serve.

What they specialise in

How they've shifted over time

Their earliest H2020 engagement (AIMS-2-TRIALS, from 2018) was oriented toward autism biomarker identification and measuring clinical outcomes across a broad neurodevelopmental spectrum — observational and translational in character. By 2021, their focus had shifted toward active pharmacological intervention, specifically first-in-human clinical drug trials targeting cognitive deficits in Down syndrome via CB1 receptor signaling. This suggests a progression from clinical observation toward interventional trial participation, reflecting either growing internal clinical capacity or a deliberate repositioning toward drug development partnerships.

They are moving deeper into interventional pharmacological research for Down syndrome, making them a relevant partner for any consortium developing treatments for rare neurodevelopmental or intellectual disability conditions.

How they like to work

Oasi participates exclusively as a consortium partner — they have never led an H2020 project. Their two projects are both large RIA consortia (AIMS-2-TRIALS spans the entire EU autism research community), which suggests they are comfortable operating within complex, multi-partner structures without a coordination role. They likely contribute a defined, bounded deliverable — clinical access, patient data, or trial site services — rather than intellectual leadership.

Despite only two projects, Oasi has connected with 68 unique consortium partners across 14 countries — a surprisingly broad network for a care center of this type. This reach is largely attributable to AIMS-2-TRIALS, one of the largest autism research consortia in Europe.

What sets them apart

Oasi is rare among Italian H2020 participants in that it is a dedicated non-profit care institution — not a university, hospital, or research institute — that directly hosts the patient populations targeted by neurodevelopmental trials. That gives them something most academic or pharma partners cannot offer: direct, ongoing clinical access to people with Down syndrome and autism in a residential care setting. For any consortium running clinical trials or real-world evidence studies in intellectual disability, they reduce one of the hardest bottlenecks: patient recruitment.

Highlights from their portfolio

• ICOD
  Their largest project by far (EUR 392,500), involving a first-in-human clinical trial of CB1 receptor inhibitors for cognitive improvement in Down syndrome — placing Oasi at the center of a high-stakes drug development study.
• AIMS-2-TRIALS
  Membership in one of Europe's most prominent autism research consortia, providing network reach to 68 partners across 14 countries despite contributing a minimal budget share.